188 related articles for article (PubMed ID: 15900607)
21. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
[TBL] [Abstract][Full Text] [Related]
22. Correlation between tumour and serum beta 2m expression in patients with breast cancer.
Klein T; Levin I; Niska A; Koren R; Gal R; Schachter J; Kfir B; Narinski R; Warchaizer S; Klein B
Eur J Immunogenet; 1996 Dec; 23(6):417-23. PubMed ID: 8971539
[TBL] [Abstract][Full Text] [Related]
23. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells.
Pantel K; Schlimok G; Kutter D; Schaller G; Genz T; Wiebecke B; Backmann R; Funke I; Riethmüller G
Cancer Res; 1991 Sep; 51(17):4712-5. PubMed ID: 1873815
[TBL] [Abstract][Full Text] [Related]
24. Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas.
Cruz I; Meijer CJ; Walboomers JM; Snijders PJ; Van der Waal I
Br J Cancer; 1999 Nov; 81(5):881-9. PubMed ID: 10555762
[TBL] [Abstract][Full Text] [Related]
25. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.
Baba T; Hanagiri T; Ichiki Y; Kuroda K; Shigematsu Y; Mizukami M; Sugaya M; Takenoyama M; Sugio K; Yasumoto K
Cancer Sci; 2007 Nov; 98(11):1795-802. PubMed ID: 17725806
[TBL] [Abstract][Full Text] [Related]
26. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
27. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.
Cromme FV; van Bommel PF; Walboomers JM; Gallee MP; Stern PL; Kenemans P; Helmerhorst TJ; Stukart MJ; Meijer CJ
Br J Cancer; 1994 Jun; 69(6):1176-81. PubMed ID: 8198988
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues.
Torigoe T; Asanuma H; Nakazawa E; Tamura Y; Hirohashi Y; Yamamoto E; Kanaseki T; Hasegawa T; Sato N
Pathol Int; 2012 May; 62(5):303-8. PubMed ID: 22524657
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases.
Ruiz-Cabello F; Lopez Nevot MA; Gutierrez J; Oliva MR; Romero C; Ferron A; Esteban F; Huelin C; Piris MA; Rivas C
Clin Exp Metastasis; 1989; 7(2):213-26. PubMed ID: 2493352
[TBL] [Abstract][Full Text] [Related]
30. Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice.
Pacasova R; Martinozzi S; Boulouis HJ; Ulbrecht M; Vieville JC; Sigaux F; Weiss EH; Pla M
J Immunol; 1999 May; 162(9):5190-6. PubMed ID: 10227992
[TBL] [Abstract][Full Text] [Related]
31. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
32. The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.
Glas R; Ohlén C; Höglund P; Kärre K
J Exp Med; 1994 Feb; 179(2):661-72. PubMed ID: 8294874
[TBL] [Abstract][Full Text] [Related]
33. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
34. Loss of CD59 expression in breast tumours correlates with poor survival.
Madjd Z; Pinder SE; Paish C; Ellis IO; Carmichael J; Durrant LG
J Pathol; 2003 Aug; 200(5):633-9. PubMed ID: 12898600
[TBL] [Abstract][Full Text] [Related]
35. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
36. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
Rolland P; Deen S; Scott I; Durrant L; Spendlove I
Clin Cancer Res; 2007 Jun; 13(12):3591-6. PubMed ID: 17575223
[TBL] [Abstract][Full Text] [Related]
37. MHC class I recognition by NK receptors in the Ly49 family is strongly influenced by the beta 2-microglobulin subunit.
Michaëlsson J; Achour A; Rölle A; Kärre K
J Immunol; 2001 Jun; 166(12):7327-34. PubMed ID: 11390483
[TBL] [Abstract][Full Text] [Related]
38. The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition.
Pietra G; Romagnani C; Falco M; Vitale M; Castriconi R; Pende D; Millo E; Anfossi S; Biassoni R; Moretta L; Mingari MC
Eur J Immunol; 2001 Dec; 31(12):3687-93. PubMed ID: 11745389
[TBL] [Abstract][Full Text] [Related]
39. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
40. Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules.
Tafuro S; Meier UC; Dunbar PR; Jones EY; Layton GT; Hunter MG; Bell JI; McMichael AJ
Eur J Immunol; 2001 Feb; 31(2):440-9. PubMed ID: 11180108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
